AI filing briefs · archive
Every 8-K brief, with filters
The whole archive: 33,711 AI briefs of material SEC Form 8-K filings by 4,788 companies: 2,325 written within three weeks of the filing (filed since Oct 19, 2026) and 31,386 written later, for past filings. Pick a month, or filter by date, 8-K item, tone, impact, topic or ticker.
Briefs on record33,711every one kept
Companies4,788with at least one brief
Recent filings2,325filed since Oct 19, 2026
Past filings31,386written later, in Nov 2026
Oppenheimer Holdings subsidiary Viner Finance entered into a lease on November 5, 2026, for about 221,339 rentable square feet at 32 Old Slip in Lower Manhattan, to serve as the firm's principal New York City offices. Fixed annual rent is approximately $13.3 million for the first five years after rent commencement, rising in later periods, and the company expects significant additional capital spending for furniture, equipment and technology tied to the relocation.
- Lease covers about 221,339 rentable square feet with an initial term of approximately 15.5 years.
- Rent commencement is the later of six months after final delivery of the Premises and July 1, 2028; fixed rent is about $13.3 million a year for the first five years, $14.4 million for the next five, and $15.5 million thereafter.
- Viner has an option to terminate at the tenth anniversary of rent commencement for a termination fee of a maximum aggregate of approximately $24 million.
- Oppenheimer's press release says phased move-in is targeted to begin in the first quarter of 2028.
Read the filing on SEC.gov ↗
Exascale Labs countersigned a $9.04 million firm purchase order for 16 Intel BHS 10U GPU servers with NVIDIA HGX B300 GPUs from Compal Electronics. The filing also describes a framework that would let the company buy up to 128 servers in total, but it places no minimum purchase obligation on the company, and the second order has not been placed. The filing does not describe financial results, and it is not clear how the servers will be funded or used.
- Purchase covers 16 servers at $565,000 each, for an aggregate price of $9,040,000 excluding taxes
- Down payment of $1,808,000 (20%) due within five business days of Compal's written order confirmation; remaining $7,232,000 (80%) due before shipment
- Framework allows purchases of up to 128 servers through March 31, 2027, with no minimum commitment; no order has been placed under the second framework agreement
- Company agreed to a storage arrangement and a three-year warranty from Compal; Compal and the company are described as unaffiliated
Read the filing on SEC.gov ↗
Aptevo Therapeutics reported on November 9, 2026 that it presented new preclinical data from its next-generation multispecific platform at the SITC 2026 Annual Meeting on November 7, 2026. The lab results cover APVO451, APVO452 and APVO711, which the company says showed tumor-cell killing and immune activation under conditions that suppress immune responses. The filing contains no financial results, and the data are early-stage, so the update does not change reported financials.
- Presentation made on November 7, 2026 at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting.
- APVO451 and APVO452 showed tumor-cell killing and T-cell activation under immunosuppressive conditions in preclinical studies.
- APVO711 combined CD40 activation with PD-L1 checkpoint blockade in preclinical findings.
- APVO451 and APVO452 are expected to advance into IND-enabling studies in 2027.
Read the filing on SEC.gov ↗
Canton Strategic Holdings announced that the first trades of its issuer-sponsored tokenized common stock occurred on November 4, 2026, on TSV LLC's venue on the Canton Network, under the SEC's September 17 Innovation Exemption. The filing contains no financial results, guidance, or financial figures; it describes a new trading and recordkeeping arrangement for the company's shares.
- First tokenized CNTN trades executed November 4, 2026 on TSV LLC, with Five North as seller, DRW Cumberland as buyer and Flowdesk as liquidity provider.
- Fairmint TA LLC, the company's SEC-registered transfer agent, records the tokenized shares; holders must be verified before holding or trading.
- Tokenized shares carry the same rights as CNTN stock traded on Nasdaq, according to the company, and trading is available 24/7 on the venue, subject to stated limits.
Read the filing on SEC.gov ↗
First Breach announced a supplier agreement giving it the ability to purchase up to 20 million primers per month, two additional ammunition inspection units, and a separate raw material supply agreement. The company says these steps support plans to scale ammunition production toward up to 20 million rounds per month and move toward 24-hour operations.
- Primer agreement allows purchases of up to 20 million primers per month from a strategic supplier
- Two additional ammunition inspection units added, supplementing equipment acquired earlier this year at the Hagerstown, Maryland facility
- Separate raw material supply agreement announced; no financial terms, dollar values or contract durations were disclosed
- Filing is a Regulation FD disclosure furnishing the November 3, 2026 press release; no financial results were reported
Read the filing on SEC.gov ↗
On November 5, 2026, the sponsor 21Shares US LLC gave notice to House of Doge Inc. terminating, effective immediately, a Support Services Agreement covering research, data, operational support and marketing services for the trust. The sponsor said it elected to terminate the agreement under its terms. The filing does not state a reason or name a replacement provider, and the terms of the services transition are not described.
- Notice given November 5, 2026; termination effective immediately
- Agreement is between the sponsor, 21Shares AG and House of Doge Inc.
- Services covered include research, data, operational support and marketing for the trust
- Filing states the sponsor elected to terminate under the agreement's terms
Read the filing on SEC.gov ↗
Nkarta, Inc. announced it will host a webcast on Monday, November 9, 2026, at 8:00 a.m. Eastern Time to review initial clinical data for its NKX019 cell therapy candidate in myositis and systemic sclerosis, presented at the American College of Rheumatology Convergence 2026. The filing contains no financial results, and the company did not disclose the clinical data itself in this document, so shareholders will learn the results at the webcast.
- Webcast set for Monday, November 9, 2026, at 8:00 a.m. ET
- Initial data covers NKX019 in myositis and systemic sclerosis under the Ntrust program
- Data to be presented at ACR Convergence 2026 in Orlando; replay to be archived on Nkarta's investor website
Read the filing on SEC.gov ↗
Parabilis Medicines entered into a Third Amendment to its lease for its Cambridge, Massachusetts headquarters, adding 33,525 square feet of space at the neighboring 20 Acorn Park Drive and extending the lease term through December 31, 2037. The filing describes this as a lease change, and it does not state any financial effect on the company's results.
- Amendment dated October 30, 2026, with LS 400/500 CDP, LLC, amends the 2019 headquarters lease.
- Expansion of 33,525 square feet on the first and sixth floors of 20 Acorn Park Drive begins January 1, 2028, with rent commencing January 1, 2029.
- Lease extension term runs from March 1, 2031 to December 31, 2037, with eight months of base rent abatement subject to conditions.
- The company gets an option to extend the lease for two additional five-year periods.
Read the filing on SEC.gov ↗
Kairos Pharma announced it was named a winner of the 2026 Biotech Breakthrough Awards in the Cancer Immunology Solution of the Year category for its ENV-105 (carotuximab) work in metastatic prostate cancer and non-small cell lung cancer. The filing reports no financial results, guidance, or transaction, so the award itself does not change reported financial figures.
- Award: Cancer Immunology Solution of the Year, 2026 Biotech Breakthrough Awards
- Lead candidate ENV-105 (carotuximab) is in development for metastatic prostate cancer and non-small cell lung cancer
- Press release references earlier positive interim Phase 2 efficacy data for ENV-105 with apalutamide in metastatic castration-resistant prostate cancer
- Press release dated November 5, 2026, furnished as Exhibit 99.1
Read the filing on SEC.gov ↗
Immunic, Inc. disclosed that it is hosting a Progressive Multiple Sclerosis (PMS) Research and Development Day webinar on November 5, 2026, from 12:30 p.m. to 2:00 p.m. ET. The company furnished a presentation for the event as Exhibit 99.1. The filing contains no financial results, guidance, or transaction terms.
- PMS R&D Day webinar held via video conference on Thursday, November 5, 2026, 12:30 p.m. to 2:00 p.m. ET
- Presentation dated November 5, 2026, furnished as Exhibit 99.1 and not deemed filed under Section 18 of the Exchange Act
- Forward-looking statements cite the feasibility of advancing vidofludimus calcium to a confirmatory phase 3 trial in progressive multiple sclerosis
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.